The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...

Cobenfy also contains trospium ... It is underused in the U.S. compared to some other countries because of a cumbersome blood ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...

In September, the FDA approved the first new schizophrenia treatment in decades. 1 Cobenfy (xanomeline and trospium chloride) has a new mechanism of action, and there is a lot of potential for ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

And Cobenfy's approval comes after two other recent setbacks in the late-stage schizophrenia pipeline; namely, the FDA’s rejection of Minerva Neurosciences’ application for roluperidone and ...

Cobenfy also contains trospium ... to some other countries because of a cumbersome blood testing program. The FDA started the blood tests to watch for the risk of severe neutropenia, a rare ...